The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Clinical research
Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial
Henricus J. Duckers1, MD, PhD; Jaco Houtgraaf1, MD; Christoph Hehrlein2, MD, PhD; Joachim Schofer3, MD, PhD; Johannes Waltenberger4, MD, PhD; Anthony Gershlick5, MD, PhD; Jozef Bartunek6, MD, PhD; Christoph Nienaber7, MD; Carlos Macaya8, MD, PhD; Nicholas Peters9, MD; Peter Smits10, MD, PhD; Thomasz Siminiak11, MD, PhD; Walter van Mieghem12, MD; Victor Legrand13, MD, PhD; Patrick W. Serruys1, MD, PhD
1. Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Cardiology, University Medical Center of Freiburg, Germany; 3. Universitäres Herzzentrum Hamburg, Germany; 4. Maastricht University Medical Center, The Nether
Aims: The SEISMIC study was an open-label, prospective, randomised study to assess the safety and feasibility of percutaneous myoblast implantation in heart failure patients with implanted